{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"10"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"15"}],"units":"Participants"}],"description":"Incidence and severity of chronic GVHD will be assessed based on the NIH consensus criteria and global severity scoring system. Attempts should be made to confirm the diagnosis pathologically by biopsy of target organ(s).","groups":[{"description":"Conditioning Regimens\n\n* fludarabine and busulfan +/- thymoglobulin\n* fractionated total body irradiation and cyclophosphamide\n* busulfan and cyclophosphamide\n* single dose total body irradiation and cyclophosphamide\n\nDay -2 = GvHD prophylaxis\n\nDay 0 or +1 = PBSC transplant\n\nDay +7 until neutrophil engraftment = G-CSF 5 ug/kg/day","id":"OG000","title":"Arm 2 - Recipient"}],"paramType":"COUNT_OF_PARTICIPANTS","populationDescription":"6 participants are not evaluable for this outcome measure as they came off study prior to the start of chronic GvHD assessments.","reportingStatus":"POSTED","timeFrame":"Day 100-1 year","title":"Rate of Chronic Graft vs. Host Disease (GvHD) (Recipient Only)","type":"SECONDARY","unitOfMeasure":"Participants"}